PARIS: Eurofins Scientific (Paris:ERF) reported a 5.3% year-on-year increase in revenues to €5.415 billion for the first nine months of 2025, driven by organic growth and acquisitions, despite a -1.5% foreign exchange headwind and one fewer public working day compared to the same period last year.
Organic revenue growth reached 4.0%, adjusted for calendar effects, with strong contributions across geographies. Europe posted 3.5% organic growth led by Food & Feed and Environment Testing, while North America matched the pace amid continued softness in BioPharma Services. The Rest of the World delivered 8.4% organic growth, supported by robust performance in all testing segments.
Start-ups added 0.6% to organic growth, with eight new laboratories and 22 blood collection points launched during the period.
In Q3 2025, organic growth accelerated to 4.2%, with reported revenues rising 4.6% to €1.803 billion.
Eurofins reaffirmed its FY 2025 and FY 2027 objectives, noting that a stronger Euro—particularly against the U.S. Dollar—could reduce FY 2025 reported revenue by up to 3% and EBITDA margin by 20 basis points if current exchange rates persist.
CEO Dr. Gilles Martin said the group remains on track to expand margins and sustain long-term growth, citing continued innovation, digitalisation, and strategic investments. He added that Eurofins had completed the acquisition of SYNLAB’s Spanish diagnostics operations and repurchased shares, while maintaining its target leverage range of 1.5x to 2.5x.
“We are confident in delivering our mid-term financial profile of strong organic revenue growth, improved profit margin, lower SDIs, and higher cash conversion,” Martin said.
Revenue Breakdown by Region
| Region | 9M 2025 Revenue (€m) | Y-o-Y Growth % | Organic Growth % |
|---|---|---|---|
| Europe | 2,805 | 7.0% | 2.7% |
| North America | 2,031 | 2.9% | 2.9% |
| Rest of the World | 579 | 5.8% | 8.1% |
| Total | 5,415 | 5.3% | 3.3% |